A Quebec court has granted Health Canada a permanent injunction barring Canlab Research from selling unauthorized injectable peptides, after the company failed to comply with an earlier order to stop. The action follows a period in which peptide-related hashtags drew more than 130,000 Instagram…
Health Canada has obtained a permanent injunction against Canlab Research, a Quebec-based company, prohibiting it from selling unauthorized injectable peptides in Canada. A Quebec court granted the injunction in June. The year of the order was not given, and neither the specific peptide products Canlab Research sold nor the company's principals were identified in the public record of the case.
The injunction was not the regulator's first move. Health Canada had ordered Canlab Research to stop selling the products, and the company did not comply. That sequence matters. An administrative stop-sale order depends on the seller's willingness to obey it. Once a company has demonstrated that it will not, the regulator's only realistic escalation is to a court, where disobedience carries consequences beyond a letter or a fine. The court action converts an instruction that had already been ignored into a judicial prohibition that the company breaches at the risk of contempt proceedings.
A permanent injunction is a final order, not a provisional one. It does not expire, and it binds Canlab Research until a court modifies or lifts it. But its scope is narrow in ways the public record makes clear: it addresses Canlab Research's sale of unauthorized injectable peptides in Canada, it does not name other sellers or the people who run the company, and it does not order a recall of products already sold or seized inventory. The company is barred from continuing the conduct; the consequences of what it already did are left to other processes.
The order lands at a moment of unusual commercial pressure around the peptide category. By May 2026, peptide-related hashtags had generated more than 130,000 posts on Instagram and 230 million views on TikTok, according to a content analysis published in JAMA and co-authored by Kyle Ganson, professor of social work at the University of Toronto. Because the injunction's year was not given, the decision cannot be placed on a timeline relative to those figures. If the June ruling predates May 2026, the social-media totals show how little a single enforcement action moved the conversation. If it came afterward, they describe the scale of the market the court was being asked to address. Either way, one order against one Quebec seller does not shift numbers of that magnitude. It draws a line around one channel in a distribution system that runs across provinces, platforms, and national borders.
Canadian drug law requires market authorization before a therapeutic product may be sold for human use. A product sold without it has not been assessed for safety, efficacy, or quality by the regulator. The word "injectable" raises the standard further. Injectable drugs bypass the digestive tract and deliver their contents directly into tissue or the bloodstream, so the bar for sterility, formulation, and manufacturing control is higher than for products that are swallowed. An unauthorized injectable peptide therefore carries two unexamined risks at once: the risk of the molecule itself and the risk of the product's manufacture, which no regulator has inspected.
An approved injectable is manufactured to defined standards. The active ingredient is made under controlled conditions, the finished product is tested for sterility and for pyrogens, the concentration is verified, and each lot can be traced if a problem appears. None of those assurances attaches to an unauthorized product. Even in the uncommon case where the peptide is the molecule it claims to be and is pure by laboratory analysis, the chain from synthesis to syringe can introduce contamination, degradation, or error at every step: the water used to reconstitute it, the vial's sterility, the concentration actually delivered by a mislabeled or unlabeled container, and the competence of the person doing the injection. The regulatory question is therefore not only whether the molecule works. It is whether the thing in the vial is the molecule, at the labeled amount, in a form safe to put into the body. Approval systems exist because those questions cannot be answered by a seller's website.
The court order binds Canlab Research by name. It runs against the company wherever it operates in Canada, and continued sale of unauthorized injectable peptides would expose the company to contempt-of-court proceedings, which can bring fines, seizure of assets, or other sanctions determined by the court. That is the practical difference between the earlier compliance order and the injunction. The first put the company on notice. The second put the company's continued operations on the line.
What the injunction does not do is as important as what it does. It does not remove the products from the hands of consumers who already bought them. It does not name the telehealth services, compounding pharmacies, or chemical suppliers that may have supplied the company. It does not establish a legal precedent about the specific peptides involved, because the products were not identified. In effect, the regulator has removed one named seller from one market while the underlying distribution network, and the online demand that feeds it, continues to operate.
Health Canada has also issued public warnings about unauthorized injectable peptides, cautioning consumers against them. The reception of those warnings is uneven. Some consumers dismiss the regulator as financially motivated rather than protective. That skepticism matters because the people who hold it are the same audience that online peptide marketing targets. A warning only works if the person receiving it trusts the source, and the promotional content that surrounds the products is designed, in part, to undermine that trust.
The JAMA paper that supplies the scale figures is a social-media content analysis of peptide-related hashtags on Instagram and TikTok. Its population is the platform content that carried those hashtags, and its measured endpoints are aggregate counts: more than 130,000 Instagram posts and 230 million TikTok views, both measured through a May 2026 cutoff. The paper's full methodology, sample size, and publication date have not been disclosed in public detail.
Read together, the two numbers describe an amplification dynamic. The totals imply an average of no more than roughly 1,800 views per post if the reported post count is anywhere near the true denominator. That ratio is the signature of a topic distributed by recommendation algorithms rather than by follower networks alone: a relatively small volume of creator content is reaching an audience far larger than the creators' own followings. TikTok's design pushes content to viewers who have not asked for it, based on engagement signals. For a product category sold through direct-to-consumer channels, that is exactly the distribution pattern a marketer would want.
Hashtag counts measure salience, not behavior. The figures do not reveal how many viewers purchased a peptide, injected one, or were harmed. They also lump together content of very different kinds: vendor advertisements, telehealth promotions, clinician explanations, user self-reports, and warnings. A person counting protein bars by hashtag would not be able to distinguish a nutritionist's review from an energy drink ad. The same limitation applies here, and it cuts both ways: the counts overstate the amount of genuine endorsement and understate the amount of raw commercial promotion, because promotional content tends to be posted repeatedly across accounts while educational content is made once.
Two features of the reported numbers deserve caution in either direction. A video that is watched repeatedly counts toward the platform's total each time it plays, so 230 million views is a measure of exposure events, not a count of distinct people reached. Conversely, hashtag data capture only content labeled with the tags the researchers chose; peptide content that avoids hashtags, or that uses misspellings and coded language, is invisible to the count. The true audience may be larger or smaller than the headline figure, and the number of distinct individuals seeing peptide promotion is unknowable from platform totals. What is knowable is direction: the category generates enough sustained content to keep the topic in front of millions of viewers on an ongoing basis, which is the precondition for a direct-to-consumer market to exist at all.
What the counts do establish is the scale of the information environment in which a person decides whether to use a product like BPC-157 or melanotan. Messages at that volume cannot be countered one conversation at a time. Ganson points to the delivery system that converts online interest into prescriptions. "We've just seen an advent of virtual online health clinics … there's a lot of loopholes that are happening within that system," he said. Virtual clinics can pair a social-media audience with a prescription and a shipped vial across provincial and national lines, which is why a single company's injunction is only a partial remedy.
Peptides are short chains of amino acids linked by peptide bonds. Many occur naturally in the body, where they act as chemical messengers or help build proteins involved in metabolism, growth, and tissue repair. Because digestive enzymes readily break peptides apart, most are administered by injection rather than swallowed. That biological fact is the reason the gray market is an injectable market: the route is not a marketing choice but a requirement of the molecule class.
The category spans some of the most carefully studied drugs in medicine. Insulin has been used for almost a century, and its dosing, adverse effects, and manufacturing standards are known because it has been studied in humans at scale for decades. T-20 is a peptide prescribed for HIV. Ozempic and Mounjaro are GLP-1 peptides used for diabetes and weight loss. The GLP-1 class works by mimicking an incretin hormone released from the gut after eating, which stimulates insulin secretion in a glucose-dependent way and suppresses appetite. Those drugs transformed treatment of type 2 diabetes and obesity, and their commercial success changed public perception of the entire peptide category.
" GLP-1s have sort of normalized peptides as a particularly safe, effective tool," Ganson said. That halo now extends to compounds with far less support, marketed online for muscle growth, weight loss, and anti-aging without an adequate understanding of their risks. BPC-157 and KPV have little or no human evidence behind them. Retatrutide has shown promising clinical-trial results for weight loss and metabolic effects but has not been approved by regulators. The difference between an approved drug and a promising trial molecule is not cosmetic. Approval follows a completed, regulator-audited evidence package. A promising trial is a stage on that path, not the destination.
The experimental side of the market spans molecules of very different sizes and presumed targets. BPC-157 is a synthetic 15-amino-acid peptide, a pentadecapeptide, that emerged from research on a protein found in gastric juice and is promoted mainly for tendon, ligament, and muscle healing. KPV is far smaller, a three-amino-acid fragment with anti-inflammatory activity in experimental systems. Retatrutide is an engineered agonist that acts on the GIP, GLP-1, and glucagon receptors at once, which is why its effects and its risks cannot be inferred from the experience of a drug that acts on one receptor. Melanotan compounds are synthetic analogs of alpha-melanocyte-stimulating hormone, the natural signal that drives pigment production. The molecules are not interchangeable, and the marketing practice of…
Peptides referenced: BPC-157, Semaglutide, Tirzepatide, Retatrutide, Glucagon, GLP-1.
Related reading: SYH2069 Injection Faces Tirzepatide in Phase 2 T2DM Trial, Seventh Victorian Case Links Counterfeit Retatrutide to Liver Toxicity, MHRA approves orforglipron, Lilly's oral GLP-1 drug, for UK use, AI-designed oral peptides get first commercial test in $100M deal.